SCHEMBL7932952

SCHEMBL7932952

CN1C(=O)CC(C)(c2cccc(NC(=O)c3cc4ccccc4o3)c2)N=C1N

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 11/20 0.64
NPC1 O15118 8/20 0.52
RAB9A P51151 8/20 0.52
TP53 P04637 6/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
PKM P14618 3/20 0.52
TSHR P16473 3/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 2/20 0.52
LMNA P02545 1/20 0.52
ALDH1A1 P00352 1/20 0.49
HTT P42858 1/20 0.49
NLRP3 Q96P20 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7944285 0.90 BACE1 (0.60) BACE1NPC1RAB9ATP53MEN1
SCHEMBL7941917 0.90 BACE1 (0.70) BACE1
SCHEMBL7942182 0.88 BACE1 (0.62) BACE1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL7941811 0.86 MAPT (0.50) BACE1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL12301588 0.85 BACE1 (0.66) BACE1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL7933954 0.85 BACE1 (0.56) BACE1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL7944382 0.84 BACE1 (0.65) BACE1SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL287267 0.84 BACE1 (0.71) BACE1
SCHEMBL287268 0.84 BACE1 (0.71) BACE1
SCHEMBL287269 0.84 BACE1 (0.71) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885NPC1 431/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.